ArticleACS omega2026
Determination of Flibanserin in Female Sexual Desire Enhancer Products by LC-MS/MS and Its Confirmation by LCMS-IT-TOF.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypoactive sexual desire disorder, a common condition among females, often goes undiagnosed due to the lack of available pharmaceutical treatments or the stigma associated with this condition. Flibanserin was initially investigated as an antidepressant but failed to demonstrate efficacy for depression; however, subsequent clinical studies revealed its potential to enhance sexual desire in some individuals, leading to its approval by the U.S. Food and Drug Administration in 2015 for the treatment of hypoactive sexual desire disorder. In this study, a novel LC-MS/MS method was developed and validated for the determination of flibanserin in commercial products marketed in Türkiye as female sexual desire enhancers. Chromatographic separation was achieved using a SunShell C18 column (100 mm × 4.6 mm, 2.6 μm), with a mobile phase consisting of 0.1% formic acid in methanol and 0.1% formic acid in water (65:35,
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.